Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Gutman

Showing results (51-60 of 59) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 59 results.
Ophthalmology|October 1, 1982
Hypopigmented iris spot. An early sign of tuberous sclerosisI Gutman, D Dunn, M Behrens, et al.
American Journal of Ophthalmology|April 15, 1991
Identification, prevention, and treatment of silicone oil pupillary block after an inferior iridectomyE Bartov, R Huna, I Ashkenazi, et al.
Journal of the National Cancer Institute|October 27, 2009
A perspective on challenges and issues in biomarker development and drug and biomarker codevelopmentSheila E Taube, Gary M Clark, Janet E Dancey, et al.
Ophthalmology|July 1, 1982
Cytomegalovirus retinitis in a young homosexual male with acquired immunodeficiencyJ Neuwirth, I Gutman, A J Hofeldt, et al.
Undersea Biomedical Research|July 1, 1992
Renal responses during a dry saturation dive to 450 mswJ M Goldinger, S K Hong, J R Claybaugh, et al.
Nature Genetics|November 28, 2002
Medical applications of microarray technologies: a regulatory science perspectiveEmanuel F Petricoin, Joseph L Hackett, Lawrence J Lesko, et al.
Biosensors & Bioelectronics|February 14, 2006
Point-of-care biosensor systems for cancer diagnostics/prognosticsSteven A Soper, Kathlynn Brown, Andrew Ellington, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2014
Evidence of clinical utility: an unmet need in molecular diagnostics for patients with cancerDavid R Parkinson, Robert T McCormack, Susan M Keating, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 22, 2017
The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future ApplicationsKenneth C Anderson, Daniel Auclair, Gary J Kelloff, et al.
Pageof 6

Showing results (51-60 of 59) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 59 results.
Ophthalmology|October 1, 1982
Hypopigmented iris spot. An early sign of tuberous sclerosisI Gutman, D Dunn, M Behrens, et al.
American Journal of Ophthalmology|April 15, 1991
Identification, prevention, and treatment of silicone oil pupillary block after an inferior iridectomyE Bartov, R Huna, I Ashkenazi, et al.
Journal of the National Cancer Institute|October 27, 2009
A perspective on challenges and issues in biomarker development and drug and biomarker codevelopmentSheila E Taube, Gary M Clark, Janet E Dancey, et al.
Ophthalmology|July 1, 1982
Cytomegalovirus retinitis in a young homosexual male with acquired immunodeficiencyJ Neuwirth, I Gutman, A J Hofeldt, et al.
Undersea Biomedical Research|July 1, 1992
Renal responses during a dry saturation dive to 450 mswJ M Goldinger, S K Hong, J R Claybaugh, et al.
Nature Genetics|November 28, 2002
Medical applications of microarray technologies: a regulatory science perspectiveEmanuel F Petricoin, Joseph L Hackett, Lawrence J Lesko, et al.
Biosensors & Bioelectronics|February 14, 2006
Point-of-care biosensor systems for cancer diagnostics/prognosticsSteven A Soper, Kathlynn Brown, Andrew Ellington, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2014
Evidence of clinical utility: an unmet need in molecular diagnostics for patients with cancerDavid R Parkinson, Robert T McCormack, Susan M Keating, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 22, 2017
The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future ApplicationsKenneth C Anderson, Daniel Auclair, Gary J Kelloff, et al.
Pageof 6